surmount-1 tirzepatide weight loss results reduction over time in tirzepatide‐treated participants by early weight response: Post hoc analysis in SURMOUNT‐1 - Ard - 2025 - Diabetes, Obesity and Metabolism surmount-1 trial tirzepatide weight loss

Bremelanotide is the FDA-approved drug product containing PT-141 as the active pharmaceutical ingredient, manufactured under cGMP standards with verified batch potency and purity testing

Lilly injects another $5.3bn in Indiana plant to up tirzepatide production Eli Lilly has committed an additional $5.3 billion to bolster capacity to manufacture active pharmaceutical ingredients (API) for its tirzepatide products, Zepbound and Mounjaro

Members achieve up to 11 pounds of weight loss in 30 days and up to 17 pounds in 60 days

Patients are responsible for confirming eligibility

All parameters were successfully estimated (relative standard error 11%) in the final model using data from the nine clinical trials (Table 4)

The active ingredient in Wegovy is semaglutide, and dulaglutide in Trulicity